A case of deep venous thrombosis in a patient with de novo hyperthyroidism

Trombosis venosa profunda en un paciente con hipertiroidismo de novo. Presentación de caso

Venous thrombosis is a clinical condition that occurs when a thrombus forms and obstructs the lumen of a vein constituting a risk for pulmonary embolism. Pathophysiology features Virchow’s triad, that is, hypercoagulability, blood flow alterations and vascular endothelial damage. Risk factors include, cancer, prolonged length of hospital stay, major surgery, major trauma and thrombophilias, although, identifying the etiological factor is impossible in 25 to 50% of all cases. A case is presented in a man with clinical presentation and diagnosis of deep venous thrombosis who had been managed with coumarin before consulting to our institution. He came to Hospital Infantil Universitario de San José for presenting an increase of the inflammatory signs on his right leg. At admission, a greater area was affected by venous thrombosis and subtherapeutic INR values were evidenced despite patient had received optimal doses of coumarin derivatives. He presented tachycardia and episodes of diaphoresis during his hospital stay. A diagnosis of hyperthyroidism associated with high concentrations of coagulation factor VIII was documented.

1. Vaya A, Mira Y, Martinez M, Villa P, Ferrando F, Estelles A, et al. Biological risk factors for deep vein thrombosis. Clin Hemorheol Microcirc. 2002;26:41–53.

2. Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular trends in incidence and mortality of acute venous thromboembolism: The AB-VTE Population-Based Study. Am J Med. 2016.


3. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28:370–2.

4. Vázquez FJ, Posadas-Martínez ML, Vicens J, de Quirós FGB, Giunta DH. Incidence rate of symptomatic venous thromboembolic disease in patients from a medical care program in Buenos Aires, Argentina: A prospective cohort. Thromb J. 2013;11:1.

5. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism a statement for healthcare professionals from the Council on Thrombosis (in Consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996;93: 2212–45.

6. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107 23 Suppl 1:I4–8.

7. Squizzato A, Romualdi E, Büller HR, Gerdes VEA. Thyroid dysfunction and effects on coagulation and fibrinolysis: A systematic review. J Clin Endocrinol Metab. 2007;92: 2415–20.

8. Erem C, Ersoz H, Karti SS, Ukinc K, Hacihasanoglu A, Değer O, et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest. 2002;25:345–50.

9. Rogers JS, Shane SR, Jencks FS. Factor VIII activity and thyroid function. Ann Intern Med. 1982;97:713–6.

10. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer P, Pijl H, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid. 2001;11:153–60.

11. Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab. 2007;92:3006–12.

12. Van Zaane B, Squizzato A, Huijgen R, van Zanten AP, Fliers E, Cannegieter SC, et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: A case-control study. Blood. 2010;115:4344–9.

13. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol. 1997;136:1–7.


14. Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: A 5-year follow-up study. J Thromb Haemost. 2010;8:2176–81.

15. Rengifo HM. Hipertiroidismo. En: Sociedad Colombiana de Endocrinología. Fascículo tiroides [Internet]. 2011 [revisado 28 Sep 2016]. Disponible en: http://www.endocrino.org.co/wp-content/uploads/2015/12/Hipertiroidismo.pdf

16. Maes J, Michotte A, Velkeniers B, Stadnik T, Jochmans K. Hyperthyroidism with increased factor VIII procoagulant protein as a predisposing factor for cerebral venous thrombosis. J Neurol Neurosurg Psychiatry. 2002;73:458.

17. Franchini M, Lippi G, Targher G. Hyperthyroidism, venous thrombosis: a casual or causal association? A systematic literature review. Clin Appl Thromb Hemost. 2011;17: 387–92.

18. Debeij J, Dekkers OM, Asvold BO, Christiansen SC, Naess IA, Hammerstrom J, et al. Increased levels of free thyroxine and risk of venous thrombosis in a large population-based prospective study. J Thromb Haemost. 2012;10:1539–46.

19. Debeij J, Cannegieter SC, van Zaane B, Smit JWA, Corssmit EPM, Rosendaal FR, et al. The effect of changes in thyroxine and thyroid-stimulating hormone levels on the coagulation system. J Thromb Haemost. 2010;8:2823–6.


20. Stuijver DJF, van Zaane B, Romualdi E, Brandjes DPM, Gerdes VEA, Squizzato A. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors. Thromb Haemost. 2012;108:1077–88.

21. Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, Guidi GC, et al. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. J Thromb Thrombolysis. 2009;28:362–5.

22. Van Zaane B, Squizzato A, Debeij J, Dekkers OM, Meijers JCM, van Zanten AP, et al. Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: A controlled randomized crossover study. J Thromb Haemost. 2011;9:1816–24.

23. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133 6 Suppl:454S–545S.

24. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 2 Suppl:e419S–24S.

25. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy1. J Am Coll Cardiol. 2003;41:1633–52.

26. Akin F, Yaylali GF, Bastemir M, Yapar B. Effect of methimazole on warfarin anticoagulation in a case of Graves’ disease. Blood Coagul Fibrinolysis. 2008;19: 89–91.